On Monday, Sensorion unveiled new data from its Phase 2a proof-of-concept clinical trial in ototoxicity induced by the anti-cancer drug cisplatin.

These preliminary data show that SENS-401 benefits from a favorable safety profile when administered continuously for up to eleven weeks in adult patients receiving cisplatin-based chemotherapy.

In a press release, Sensorion adds that recruitment is progressing well, with over a third of the required population included in the study.

The biotech company plans to report progress on its Phase 2a proof-of-concept study at the World Congress of Audiology, to be held in September 2024, in Paris.

As for the Phase 2a study conducted on SENS-401 in the prevention of residual hearing loss after cochlear implantation, it is also progressing as planned, adds the company, which expects to complete patient recruitment early next year.

Following these announcements, Sensorion shares were little changed (-0.1%) on Monday on the Paris Bourse, after having gained up to 3% in the course of the morning.

Copyright (c) 2023 CercleFinance.com. All rights reserved.